Mark Emberton is a prominent British urologist and academic researcher specializing in the diagnosis and treatment of prostate cancer. He serves as a Professor of Interventional Oncology at University College London (UCL) and is a consultant urological surgeon at University College London Hospitals NHS Foundation Trust (UCLH). From 2015 to 2023, he held the position of Dean of the Faculty of Medical Sciences at UCL.
Academic and Clinical Career Emberton’s professional focus centers on improving the precision of prostate cancer detection and management. He is a Fellow of the Royal College of Surgeons (FRCS) and has spent much of his career investigating ways to reduce the morbidity associated with traditional prostate cancer treatments. His clinical practice and research are primarily based in London, where he has held various leadership roles within the academic medical community.
Research and Contributions Emberton is widely recognized for his advocacy of magnetic resonance imaging (MRI) in the diagnostic pathway of prostate cancer. He was a lead investigator in several landmark clinical trials that have influenced international clinical guidelines:
- PROMIS (Prostate MRI Imaging Study): This trial demonstrated that using multi-parametric MRI (mpMRI) as a triage tool before a biopsy could identify more clinically significant cancers while allowing many men to avoid unnecessary biopsies.
- PRECISION Trial: This study established that MRI-targeted biopsies are superior to standard, non-targeted systematic biopsies for detecting high-grade prostate cancer.
In addition to diagnostic advancements, Emberton is a leading proponent of focal therapy. This approach involves treating only the cancerous lesions within the prostate gland using technologies such as High-Intensity Focused Ultrasound (HIFU) or cryotherapy. The objective of focal therapy is to achieve oncological control while minimizing side effects such as urinary incontinence and erectile dysfunction, which are common risks associated with radical prostatectomy or radiotherapy.
Recognition Emberton has published extensively in peer-reviewed journals, including The Lancet and the New England Journal of Medicine. His work is frequently cited in the field of urology and oncology. He is a member of several professional organizations and often contributes to international consensus meetings regarding the management of localized prostate cancer.